Current Report Filing (8-k)
June 23 2015 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2015 (June 19, 2015)
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-51820 |
|
77-0567768 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
Alexza Pharmaceuticals, Inc.
2091 Stierlin Court
Mountain View, California |
|
94043 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 3 Securities and Trading Markets
Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
(a)
On June 19, 2015, Alexza
Pharmaceuticals, Inc. (Alexza) received a notice (the Notice) from the Nasdaq Stock Market (NASDAQ) indicating that Alexzas common stock (Common Stock) no longer meets the continued listing
requirement as set forth in NASDAQ Rule 5550(b)(2) based on the market value of Alexzas listed securities for the preceding 30 business days. The minimum market value of listed securities for continued listing on the Nasdaq Capital Market is
$35 million.
Under NASDAQ Rule 5810(c)(3)(C), Alexza has a 180 calendar day grace period from the date of the Notice to regain compliance
by meeting the continued listing standard. The continued listing standard will be met if the market value of Alexzas listed securities closes at $35 million or more for a minimum of 10 consecutive business days during such grace period. If
Alexza is unable to regain compliance during the 180 calendar day grace period and receives a delisting determination from NASDAQ it may, at that time, request a hearing to remain on The Nasdaq Capital Market, which request will ordinarily suspend
such delisting determination until a decision by NASDAQ subsequent to the hearing.
There can be no assurance that Alexza will be
successful in maintaining its listing of the Common Stock on The Nasdaq Capital Market. This could impair the liquidity and market price of the Common Stock. In addition, the delisting of the Common Stock from a national exchange could materially
adversely affect Alexzas access to capital markets, and any limitation on market liquidity or reduction in the price of the Common Stock as a result of that delisting could adversely affect Alexzas ability to raise capital on terms
acceptable to Alexza, or at all.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ALEXZA PHARMACEUTICALS, INC. |
Date: June 23, 2015 |
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Thomas B. King |
|
|
|
|
|
|
Thomas B. King President and Chief Executive
Officer |